Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab or Teclistamab with PD-1 Inhibitor in Relapsed/Refractory Multiple Myeloma
NCT05338775Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of talquetamab and teclistamab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events, Number of Participants with Adverse Events by Severity and 2 more. Started May 2022; status: active, not recruiting.
02
Drugs
talquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05338775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338775.